Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

S0360000

Selegiline hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

R-(−)-Deprenyl hydrochloride, (R)-(−)-N,α-Dimethyl-N-(2-propynyl)phenethylamine hydrochloride, R(−)-N-α-Dimethyl-N-2-propynyl-benzeneethanamine hydrochloride, Selegiline hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C13H17N · HCl
Numéro CAS:
Poids moléculaire :
223.74
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

selegiline

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

Cl[H].C[C@H](Cc1ccccc1)N(C)CC#C

InChI

1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1

Clé InChI

IYETZZCWLLUHIJ-UTONKHPSSA-N

Informations sur le gène

human ... MAOB(4129)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Selegiline hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Selective MAO-B inhibitor; anti-Parkinsonian agent.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Exclamation mark

Mention d'avertissement

Warning

Mentions de danger

Conseils de prudence

Classification des risques

Acute Tox. 4 Oral - STOT SE 3

Organes cibles

Central nervous system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Dhaval R Kalaria et al.
International journal of pharmaceutics, 438(1-2), 202-208 (2012-09-08)
The objective was to investigate the anodal iontophoresis of the MAO-B inhibitors rasagiline (RAS) and selegiline (SEL) across porcine and human skin in vitro. Passive delivery of RAS and SEL from aqueous solution was minimal; however, increasing current density from
Orit Bar-Am et al.
European journal of pharmacology, 683(1-3), 226-230 (2012-04-03)
Cardiovascular baroreceptor responsiveness of conscious rats treated with selective inhibitors of monoamine oxidase (MAO) types A and B was determined by measurement of blood pressure (BP) and heart rate (HR) responses to intravenous injection of phenylephrine and sodium nitroprusside. Treatment
Giovanni Fabbrini et al.
Clinical neuropharmacology, 35(3), 134-140 (2012-05-18)
Selegiline at the doses used in Parkinson disease is a selective irreversible monoamine oxidase type B inhibitor, which potentiates dopaminergic function in the brain, and is used as monotherapy in early Parkinson disease or in combination with levodopa in more
Jorge A Zavala et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 19(9), 1298-1299 (2012-06-23)
Pramipexole is a non-ergot dopamine agonist that is used frequently as a single therapy or in combination for the management of Parkinson's disease. Common side effects are daytime drowsiness, hypotension, hallucinations and compulsive behaviour. We describe a patient who developed
Wakako Maruyama et al.
Journal of neural transmission (Vienna, Austria : 1996), 120(1), 83-89 (2012-08-16)
Neuroprotection has been proposed in neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases, to delay or halt disease progression or reverse neuronal deterioration. The inhibitors of type B monoamine oxidase (MAO), rasagiline and (-)deprenyl, prevent neuronal loss in cellular and

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique